期刊
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
卷 6, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s40164-017-0072-7
关键词
Bispecific antibody; Chemical conjugation; Quadroma; scFv; Cancer immunotherapy; Immune escape
资金
- National Natural Science Foundation of China [30971291, 81400176, 81572993]
- CAMS Initiative for Innovative Medicine [2016-I2M-1-007, 2016-I2M-3-013]
During the past two decades, a great evolution of bispecific antibodies (BsAbs) for therapeutic applications has been made. BsAbs can bind simultaneously two different antigens or epitopes, which leads to a wide range of applications including redirecting T cells or NK cells to tumor cells, blocking two different signaling pathways, dual targeting of different disease mediators, and delivering payloads to targeted sites. Aside from approved catumaxomab (anti-CD3 and anti-EpCAM) and blinatumomab (anti-CD3 and anti-CD19), many more BsAbs are now in various phases of clinical development. Here, this review focus on the development of bispecific antibodies and their applications in tumor immune escape.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据